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Abstract Squamous cell carcinomas (SCCs) arising in the
oral cavity are associated with poor survival, mainly due to
metastatic disease. In contrast, skin SCCs rarely metastasize
and are usually curable. To study influence of tongue and
skin stroma on cancer growth and induction of lymphangio-
genesis, xenograft tumors of human carcinoma cells were
established either in tongue or skin of BALB/c nude mice.
Two oral and two skin SCC cell lines were used, as well as
an endometrial adenocarcinoma cell line. Tongue tumors
established from all cell lines were larger than
corresponding skin tumors. Peritumoral lymphatic vessel
density was up to five times higher in tongue than in
corresponding skin tumors, and mRNA level of the
lymphangiogenic growth factor vascular endothelial growth
factor (VEGF)-C was twice as high in tongue tumors
compared with corresponding skin tumors. Contrary to
lymphatic vessel density, blood vessel density was higher in
skin tumors than in tongue tumors. In a cohort of patient
samples, lymphatic vessel density was found to be higher in
tongue SCCs compared with skin SCCs, supporting a
clinical relevance of our findings. Our results show that the
tumor stroma has a profound impact on cancer growth and
induction of lymphangiogenesis and angiogenesis. The
difference in lymphatic vessel density between tongue and
skin tumors may be important in directing metastatic
potential of tumors arising in these organs.
Keywords Mouse model.Orthotopic.Oral cancer.Skin
cancer.Lymphangiogenesis.Angiogenesis
Introduction
Squamous cell carcinomas (SCCs) can arise in various
locations of the body, including skin, oral mucosa,
esophagus, lungs and cervix, but the tumor aggressiveness
is dependent on the “host” organ. Oral SCCs are charac-
terized by an aggressive behavior and associated with a low
5-year survival rate, mainly because of metastatic disease
[1, 2]. In contrast, skin SCCs seldom metastasizes, and
most patients have a very good prognosis [3].
It is well recognized that cancer growth and progres-
sion are strongly influenced by the non-malignant part of
the tumor, the tumor stroma, which is composed of an
extracellular matrix (ECM) and various cells types such
as fibroblasts, smooth muscle cells, endothelial cells and
inflammatory cells [4]. Malignant cells communicate with
and modify their microenvironment through the release of
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DOI 10.1007/s00428-010-0980-yvarious molecules, as well as by cell–cell and cell–matrix
contacts. When stimulated, the stromal cells influence
cancer progression by producing growth factors and
proteases that modulate growth, apoptosis, angiogenesis,
lymphangiogenesis, invasion and metastasis [5, 6].
The importance of angiogenesis in cancer progression is
well documented [7]. Less focus has been on the role of
lymphangiogenesis, although SCCs mainly metastasize via
lymphatic vessels [8]. The lack of reliable markers of
lymphatic endothelial cells has held back studies on
lymphangiogenesis, but recently more specific markers
have been identified which have given rise to increased
knowledge of the role of the lymphatic system in cancer
[9–11]. Many cancer types, such as melanomas, oral,
cervical, and non-small cell lung cancers can induce
lymphangiogenesis, and lymphatic vessel density is often
correlated with metastases and poor survival [12–15].
A large number of cytokines and growth factors are
reported to affect angiogenesis and lymphangiogenesis.
Vascular endothelial growth factor (VEGF)-C and VEGF-D
are important lymphangiogenic growth factors [16, 17],
mediating proliferation, survival and increased migration of
cultured human lymphatic endothelial cells [17]. VEGF-C
knockout mice die in utero due to a complete lack of
lymphatic vessels and subsequent accumulation of fluid in
the tissues [16]. The VEGF-C deficient phenotype can be
r e s c u e db yV E G F - D[ 16], indicating an overlapping
function of these growth factors. Both factors are secreted
from various cell types in an active form that can bind their
principal receptor, VEGFR-3. In normal adult tissue, this
receptor is restricted to lymphatic endothelial cells, but
can also be expressed on tumor vascular endothelial cells
[10, 18–20]. In the extracellular environment VEGF-C and
VEGF-D can be processed by proteases to a mature form
with higher affinity for VEGFR-3 [19, 21].
In order to investigate the role of the stroma for tumor
growth and lymphangiogenesis, we established a xenograft
model in which different human carcinoma cell lines were
injected in the tongue or the skin of BALB/c nude mice.
Cancer cells are reported to grow faster and be more
aggressive in the orthotopic environment compared with a
heterotopic environment [22, 23]. To control for this effect,
we used cell lines established from skin and tongue SCCs,
as well as an endometrial adenocarcinoma cell line.
Independently of orthotopic or heterotopic growth of the
tumor cells, we found that the tumor stroma had a strong
impact on several aspects of tumor progression, including
growth and lymphangiogenesis.
Materials and methods
Cell lines and culturing
The human cancer cell lines and culture media used are
listed in Table 1. The HSC-4 cell line was a kind gift from
Professor M. Yanagishita, Tokyo Medical and Dental
University, Japan. The establishment of the UT-SCC-7
and UT-SCC-12A cell lines is done as described in
Grénman et al. [24]. The SCC-25 cell line was purchased
from ATCC (Manassas, VA), and the Ishikawa cells from
Sigma-Aldrich (St. Louis, MO). All cell lines were
incubated in a humidified atmosphere of 5% CO2 at 37°C.
Animals and establishment of xenograft tumors
To determine a suitable number of cells to be injected, pilot
studies were performed. A concentration of 300,000 cells in
25 μl 0.9% NaCl was chosen. Cultured cells were detached
by trypsin treatment (0.25% in PBS with 0.05%
Na2EDTA), washed once in serum containing cell culture
medium, once in 0.9% NaCl and thereafter resuspended in
0.9% NaCl at a concentration of 12 million cells/ml. Six- to
8-week-old BALB/c nude mice (Harlan Laboratories,
Table 1 Cell lines and culture media
Cell line Origin Medium
SCC-25 Tongue SCC DMEM/HamF-12, 10% FBS, 0.5 mM L-glutamine, 50 U
penicillin and 50 μg/ml streptomycin, 400 ng/ml
hydrocortisone
HSC-4 Lymph node metastasis of tongue SCC DMEM, 10% FBS, 0.5 mM L-glutamine, 50 U penicillin and
50 μg/ml streptomycin
UT-SCC-12A Skin SCC, nose DMEM, 10% FBS, 0.5 mM L-glutamine, 50 U penicillin
and 50 μg/ml streptomycin, 0.1 mM non-essential amino acids
UT-SCC-7 Lymph node metastasis of skin SCC, regio temporalis DMEM, 10% FBS, 0.5 mM L-glutamine, 50 U penicillin and
50 μg/ml streptomycin, 0.1 mM non-essential amino acids
Ishikawa Endometrial adenocarcinoma RPMI 1640, 10% FBS, 0.5 mM L-glutamine, 50 U penicillin and
50 μg/ml streptomycin
678 Virchows Arch (2010) 457:677–692Indianapolis, IN) were anaesthetised with a mixture of
0 . 5m gk e t a m i n ea n d0 . 1m gx y l a z i n eh y d r o c h l o r i d e
subcutaneously before 25 μl of cancer cell suspension
was injected into the anterior part of the tongue or
subcutaneously on the abdomen. For each cell line
tongue tumors were establi s h e di n1 2m i c ea n ds k i n
tumors in 12 mice, except for the UT-SCC-7 cell line
from which six tongue and six skin tumors were
established. The mice were weighed every second day
to ensure that they did not lose more than 10% of their
body weight, and were sacrificed with CO2 after
5–28 days. Tumors were either fixed in a Zn-based
fixative (ZBF) (36.7 mM ZnCl2,2 7 . 3m MZ n A c 2×2H2O
a n d0 . 6 3m MC a A c 2 in 0.1 mol/l Tris pH 7.4) or
submerged in RNAlater (Sigma-Aldrich St. Louis, MO)
immediately after the mice were sacrificed. Draining
lymph nodes were fixed in ZBF, whereas liver and lungs
were fixed in 4% neutral buffered formalin (NBF). Blood
samples were collected, mixed with heparin (15 U/ml
heparin blood) and centrifuged at 11,000×g for 5 min
before plasma was isolated. The project was approved by
the Norwegian Animal Research Authority.
Metastasis
ZBF-fixed lymph nodes were paraffin embedded, sectioned
and H/E-stained to look for metastases. The presence of
metastases was confirmed by immunohistochemical stain-
ing with a pan cytokeratin antibody (Zymed laboratories,
purchased from Invitrogen, Carlsbad, CA). NBF-fixed
livers and lungs were sliced and examined for metastases
under a dissecting microscope. In addition, lymphatic
permeation of cancer cells was assessed on sections of
tongue and skin tumors of the various cell lines immuno-
histochemically stained with the lymphatic endothelial cell
marker Lyve-1. The sections/samples were scored as
positive if clusters of cancer cells were found within one
or more lumens with Lyve-1-positive lining.
Tumor size
ZBF-fixed tongue and skin tumors were dehydrated,
paraffin embedded (oriented in the same way) and
serially sectioned to measure the size of the tumors.
During sectioning, the area of the tumor was studied
in a light microscope (Leica DM2000, Leica, Wetzlar,
Germany). The sections with the largest tumors were H/E
stained, and the tumor area was accurately measured
using a Leica Application Suite Interactive measurement
tool (Leica, Wetzlar, Germany). The mean area was
calculated based on the five largest tumors in tongue and
skin of each cell line, except for the HSC-4 cell line
where only three detectable skin tumors were found at
each time point. Tumor size was measured after 28 days
of in vivo growth for all cell lines except the UT-SCC-
12A cell line for which tumors were measured after
15 days of in vivo growth.
Immunohistochemistry
Four-micrometer thick sections of ZBF-fixed, paraffin-
embedded tissue from the mouse xenograft model or of
formalin-fixed human tongue or skin SCCs on Superfrost
Plus slides were analyzed by immunohistochemistry. The
antibodies, dilutions and incubation conditions are listed
in Table 2. Horseradish peroxidase (HRP)-labeled second-
ary antibody and diaminobenzidine (DAB)-substrate
(EnVision
+ system-HRP for rabbit primary antibodies,
Dako, Glostrup, Denmark or Ventana XT Ultra View
Universal DAB, Tucson, AZ) were used for visualization.
Immunohistochemistry was performed as previously de-
scribed [25]. The CD31 and CD68 antibodies were
monoclonal rat anti-mouse antibodies, and immunohisto-
chemical procedure for these antibodies included a linking
rabbit anti-rat antibody (Dako 1:400). Sections where
primary antibody was omitted and replaced by 1.5% normal
goat serum were used as negative controls. Staining for
Antibody Dilution Incubation
Rabbit anti-bovine cytokeratin(Pan) pab, Zymed Laboratories # 08-0059 Predilute 1 h RT
Rabbit anti-human PHH-3 pab, Millipore # 06-570 1:500 32 min., RT
Rabbit anti-human caspase-3 active pab, R&D systems # AF835 1:900 30 min., RT
Rat anti-mouse CD-31 mab, BD Pharmingen #550274 1:10 ON, 4°C
Rabbit anti-mouse Lyve-1 pab, AbCam # ab14917 1:1,000 30 min., RT
Mouse anti-human D2-40, Dako # M3619 1:25 32 min., RT
Rabbit anti-human VEGF-C pab, Zymed Laboratories # 182255 1:150 ON, 4°C
Rabbit anti-human VEGF-D pab, Santa Cruz # sc-13085 1:100 ON, 4°C
Rat anti-mouse CD-68 mab, AbCam # ab53444
a 1:600 30 min., RT
Rabbit anti-rat immunoglobulins, Dako # E0468 1:400 30 min., RT
Table 2 Antibodies
aAntigen retrieval 1.3 mg/ml
Pepsin 30 min RT
Abbreviations: RT room temper-
ature, ON over night
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Ventana (Tucson, AZ) automated immunohistochemical
stainer according to the manufacturer’s instructions. Unless
otherwise specified, staining of xenograft tumors were
performed on tumors after 28 days of in vivo growth for
all cell lines except the UT-SCC-12A cell line from which
tumors were analyzed after 15 days of in vivo growth.
Fraction of mitotic and apoptotic cells
To calculate the fraction of cells undergoing apoptosis and
mitosis, immunohistochemical staining with the apoptotic
marker active caspase-3, and the proliferation marker PHH3
were performed. Three apoptotic/mitotic hotspots were
recognized at low power magnification (40×) in three
parallel tongue and skin tumors of each cell line. The
fraction of apoptotic and mitotic cells were determined by
calculating the mean number of apoptotic or mitotic cells
per total number of cells on photographs taken with a Leica
DFC 420 camera on a Leica DM2000 microscope (Leica,
Wetzlar, Germany) of the hotpots at high-power magnifi-
cation (400×).
Determination of blood vessel density
Sections of normal tongue and skin tissue of BALB/c nude
mice, as well as tongue and skin xenograft tumors of the
various cell lines were stained with the vascular endothelial
cell marker CD31. For each cell line mean vessel density
(MVD) was calculated according to the method described
by Weidner et al. [26]. Three vascular hotspots were
recognized at low power magnification (40×) in three
parallel tongue and skin tumors of each cell line. Lumens
with CD31-positive lining were counted in each hotspot at
200× magnification to calculate the MVD. In addition,
MVD was measured by counting lumens containing
erythrocytes on H/E-stained sections. These calculations
were performed the same way as the CD31 counting,
except that five parallel tongue and skin tumors were
evaluated for each cell line, and counting was performed at
400× magnification. Vessel density was calculated in the
tumor and in the stromal tissue within a 0.5 mm radius from
the outer border of a tumor island.
Determination of lymphatic vessel density
Sections of tongue and skin xenograft tumors of each
cell line, as well as normal tongue and skin tissue of
BALB/c nude mice, were stained with the lymphatic
endothelial cell marker Lyve-1. Peritumoral lymphatic
vessel density was calculated as the mean of three
hotspots per section for at least three parallel tumors, as
a modification of the method described by Weidner et al.
[26]. Hotspots were recognized at low power magnifica-
tion and counted at 200× magnification. Each hotspot had
an area of 0.25 mm
2 and was located within a radius of
0.5 mm from the outer border of a tumor island. Only
lymphatic vessels with an evident lumen were counted.
Intratumoral lymphatic vessel density was calculated for
tumors with intratumoral lymphatic vessels. Three visual
fields containing hotspots were recognized per tumor and
counted at 200× magnification. In addition, 21 skin and 21
tongue SCCs, randomly chosen from the archives of the
Surgical Pathology Department at the University Hospital
North Norway, were immunohistochemically stained
with the lymphatic endothelial cell marker D2-40. For
each tumor, three hotspots were recognized at 100×
magnifications and counted at 200× magnification. The
mean number of lymphatic vessels per visual field was
calculated.
Immunohistochemical scoring of VEGF-C and VEGF-D
Immunohistochemical staining with antibodies against the
lymphangiogenic growth factors VEGF-C and VEGF-D
were scored according to Kobel et al. [27]. Staining
intensity of the tumor cells was designated as non-existent
(0), weak (1), moderate (2) or strong (3). The number of
positive cells was scored as no cells stained (0), less than
10% (1), 10–50% (2), 51–80% (3) or more than 80% (4).
The final score was calculated by multiplication of these
two variables.
Quantification of VEGF-C and VEGF-D mRNA
Tumor samples were separated from stroma under a
dissecting microscope and homogenized in a TissueLyzer
homogenizer (Qiagen, Hilden, Germany) with 5-mm steal
beads. Total RNA was extracted using RNeasy Fibrous
Tissue Mini kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. On-column DNase treat-
ment of the RNA samples was performed using Qiagen’s
RNase-Free DNase set according to the product manual.
Quantity and purity of the extracted RNA was deter-
mined using the NanoDrop spectrophotometer (Thermo
Fisher Scientific, Wilmington, DE), and RNA integrity
was assessed using the Experion-automated electropho-
resis system (Bio-Rad Laboratories, Hercules, CA).
VEGF-C and VEGF-D mRNA expression levels were
quantified by reverse transcription quantitative PCR (RT-
qPCR) performed on a Stratagene Mx3000P instrument
(Stratagene, La Jolla, CA). Primers for SYBR Green
based assays were purchased from Qiagen (Hilden,
Germany) (listed in Table 3). Primer specificities and
absence of primer dimers were determined by SYBR
Green melting curve analysis. Reverse transcription of
680 Virchows Arch (2010) 457:677–692total RNA was performed using Reverse Transcriptase
Core Kit (Eurogentec, SA, Searing, Belgium) with random
nonamer primers according to the manufacturer’sr e c o m -
mendations, using 200 ng RNA per 10-μl cDNA reaction.
c D N Ac o r r e s p o n d i n gt o2 0n g RNA was amplified for 40
cycles in a 25-μlP C Rm i x( R T
2Real-Time™ SYBR
Green/ROX PCR Master Mix (SA Biosciences, Frederick,
MD)). Cycling conditions: 95°C for 10 min, 40 cycles at
95°C for 30 s and 60°C for 1 min. Duplicate reverse
transcription reactions were performed for each RNA
sample, and duplicate PCR analyses were performed on
each cDNA sample. The absence of genomic DNA was
confirmed by performing a no reverse transcription
control, and absence of contaminations was assessed by
including a no template control in every run. The delta–
delta Ct method [28] was used to determine the relative
amount of target gene in the tumor samples normalized
against the average expression of the two reference genes
ACT-B and TFRC.
Quantification of myeloid cells
CD68 staining was performed to evaluate proportion of
macrophages, Langerhans cells and dendritic cells in the
inflammatory infiltrate. The number of CD68-positive
cells surrounding both tongue and skin tumors was very
low, therefore no detailed scoring of this staining was
performed. To evaluate number of mast cells in the
inflammatory infiltrate, chemical staining with May–
Grünwald–Giemsa was performed following standard
procedures on three parallel tongue and skin tumors of
each cell line. Three mast cell hotspots within a radius of
0.5 mm from the outer border of a tumor island were
recognized in each section and counted at 400× magni-
fication. Furthermore, an assessment of the inflammatory
infiltrate was made on H/E-stained sections of tongue
and skin tumors of the different cell lines. The extent of
inflammatory reaction was assessed and scored as
negligible (0), weak (1), moderate (2) or strong (3).
The proportion of neutrophils in the inflammatory
infiltrate was evaluated, based on morphological charac-
teristics, and scored as <1% (0), 1–30% (1), 31–70% (2)
or >70% (3). The number of neutrophils was then
estimated by multiplication of these two variables.
Quantification of serum amyloid P in plasma
To measure the level of the major mouse acute phase protein
serum amyloid P (SAP) in circulation, plasma from mice with
tongueandskintumorsofthevariouscelllinesweresubjected
to enzyme-linked immunoassay using a Mouse Serum
AmyloidPELISAkit(KamiyaBiomedicalCompany,Seattle,
WA). Samples were diluted 1:10,000, and the assay was
performed according to the product manual.
Statistics
Two-tailed t tests were used to evaluate differences between
tongue and skin tumors for the different parameters
analyzed. Data are presented as means±standard error of
the mean (SEM). Independent replicates (N)f o rt h e
different data are identified in tables and figure legends. P
values <0.05 were accepted as statistically significant.
Graphics and statistical analyses were performed using
SPSS 15.0 for Windows.
Results
Tumors in tongue and skin of BALB/c nude mice were
established by injecting 300,000 cancer cells at each site in
separate animals. Five different human cell lines were used,
two oral and two skin SCCs, as well as an endometrial
adenocarcinoma cell line (Table 1). The mice were
sacrificed 15 or 28 days after cancer cell injection, except
for mice with tumors of the skin SCC cell line UT-SCC-
12A. This cell line grew faster than the other cell lines in
tongue, and therefore all mice with UT-SCC-12A tumors
were sacrificed after 15 days.
All cell lines formed larger tumors in tongue than in skin
It is well known that tumor size is an important prognostic
factor. To study how the microenvironment in the tongue and
the skin affected tumor growth, we measured the size of the
tumors as described in the “Materials and methods” section.
This revealed that all cell lines formed larger tumors in the
tongue than in the skin. The average area of the SCC-25,
HSC-4 and UT-SCC-12A tongue tumors were seven to 17
Gene symbol Assay name Cat.no Amplicon length (bp) RefSeq accession number
VEGF-C Hs_VEGFC_1_SG QT00061579 96 NM_005429
VEGF-D Hs_FIGF_1_SG QT00003997 138 NM_004469
ACT-B Hs_ACTB_1_SG QT00095431 146 NM_001101
TFRC Hs_TFRC_1_SG QT00094850 81 NM_001128148
Table 3 QuantiTec primer
assays from Qiagen
Virchows Arch (2010) 457:677–692 681times larger than the corresponding skin tumors, while the
differences were smaller for tumors of the UT-SCC-7 and
Ishikawa cell lines (Figs. 1 and 2). In addition to being
smaller, the skin tumors of the UT-SCC-12A and HSC-4 cell
lines often regressed spontaneously during the first 2 weeks.
Although all mice had detectable tumors 1 week after
injection, 14 out of 18 animals injected with UT-SCC-12A
cells in the skin had detectable tumors after 14 days, and only
nine out of 18 animals injected with HSC-4 cells in the skin
had detectable tumors after 28 days. The number of cells
injected in skin was raised to five million, but still the tumors
often regressed during the first 2 weeks.
The fraction of mitotic and apoptotic cells was calculated
for the skin and tongue tumors of the various cell lines, as a
difference in one or both of these parameters would be
expected based on the observed discrepancy in tumor size.
For all cell lines a higher fraction of mitotic cells was seen
in the tongue tumors compared with the skin tumors
(Table 4), whereas the fraction of apoptotic cells showed
only minor differences between the skin and tongue tumors
for all cell lines (Table 5).
Lymph node metastases from tongue tumors were detected,
but not from skin tumors
In general, oral SCCs are characterized by frequent lymph
node metastases, while skin SCCs seldom metastasize. In
tumors from our xenograft model, regional lymph node
metastasis were detected in nine out of 18 of the tongue
tumors of the skin SCC cell line UT-SCC-12A (Fig. 3a),
and also from two out of 18 of the tongue tumors of the
Ishikawa cell line. No metastases were detected from
tongue tumors of the other cell lines or from any of the
skin tumors. Lymphatic permeation of cancer cells was
found in ten out of 31 evaluated tongue tumors (Fig. 3b)
and in four out of 27 evaluated skin tumors stained with the
lymphatic endothelial cell marker Lyve-1.
Blood vessel density was higher in skin tumors
than in tongue tumors
Sections of the various tongue and skin tumors from our
xenograft model were immunohistochemically stained
with the vascular endothelial cell marker CD31
(Fig. 4a–d), and MVD determined in order to investigate
if vascularisation was correlated to tumor size. Surpris-
ingly, the skin tumors showed a higher MVD than the
corresponding tongue tumors (data not shown). Within
some tongue tumors there were endothelial cells that had
lost CD31 positivity, evident as unstained tubular struc-
tures containing red blood cells (Fig. 4d). As this made the
CD31-based calculations somewhat uncertain, MVD was
also calculated by counting lumens containing erythro-
cytes on H/E-stained sections. These calculations con-
firmed the results obtained by counting CD31-positive
tubular structures. The MVD for skin tumors of the UT-
SCC-12A, UT-SCC-7 and Ishikawa cell lines were on
average 2.3 times higher than for the corresponding
tongue tumors, while smaller differences were seen
between skin and tongue tumors of the SCC-25 and
HSC-4 cell lines (Fig. 4e). MVD for tongue tumors of all
cell lines pooled was significantly higher than MVD for
skin tumors of all cell lines pooled (Fig. 4e). MVD was
also calculated in normal tongue and skin, by counting
CD31-positive tubular structures in hotspots in the
anterior, free moving part of the tongue as well as in the
Fig. 1 Size of tongue and skin
tumors. Graph shows mean area
in mm
2 (±SEM) of tongue
(black bars) and skin (grey bars)
tumors of the various cell lines.
N=5 for SCC-25, UT-SCC-12A,
UT-SCC-7 and Ishikawa tumors.
N=3 for skin tumors and N=5
for tongue tumors of the HSC-4
cell line. N=25 for pooled
tongue tumors, and N=23 for
pooled skin tumors of all cell
lines. *P<0.01
682 Virchows Arch (2010) 457:677–692Fig. 2 H/E staining of tongue
and skin tumors. H/E-stained
sections of representative tongue
tumors (a, c, e, g and i) and skin
tumors (b, d, f, h and j) of the
SCC-25 (a and b), HSC-4 (c and
d), UT-SCC-12A (e and f), UT-
SCC-7 (g and h) and Ishikawa
(i and j) cell lines. Labeling
indicates: t tumor, s stroma,
m striated muscle, asterisk
keratinous pearl; arrow
surface epithelium. Original
magnification, 100×
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these two sites (data not shown).
Lymphatic vessel density was higher in tongue tumors
than in skin tumors
Lymphatic vessel density is found to correlate with lymph
node metastases in many cancers. We therefore investigated
if lymphatic vessel density differed between tongue and
skin tumors in our xenograft model. Tongue and skin
tumors, as well as normal tongue and skin tissue of the
mice, were immunohistochemically stained with the lym-
phatic endothelial cell marker Lyve-1 (Fig. 5a, b). Positive
staining was seen in tubular structures. None of these
contained red blood cells, supporting that these were
lymphatic vessels. In the normal tongue and skin tissue of
the mice, no difference in lymphatic vessel density was
observed between the two different sites (results not
shown). In the tumor tissue, lymphatic vessels were mainly
seen in the stroma surrounding the tumor. In addition,
intratumoral lymphatic vessels were seen in some tumors,
primarily in the tongue. Peritumoral lymphatic vessel
density was up to five times higher in tongue compared
with skin tumors (Fig. 5c). Functional lymphatic vessels
(containing a lumen) were almost completely absent
surrounding the skin tumors of the oral SCC cell lines
SCC-25 and HSC-4. The other cell lines seemed to be able
to induce formation of new lymphatic vessels in association
with the skin tumors, but to a much lesser extent than in the
tongue. In the tongue, numerous lymphatic vessels sur-
rounded the tumors. These vessels were often concentrated
in hotspots towards the basis of the tongue. To study the
time course of lymphangiogenesis, tongue tumors of the
HSC-4 cell line were stained with Lyve-1 after 5, 10 and
15 days of tumor growth. Five days after cancer cell
injection (Fig. 6a), the number of lymphatic vessels
surrounding the tumors was about the same as in the
normal tongue, while a marked increase was seen both
within and surrounding the tumors from day 5 till days 10
and 15 after cancer cell injection (Fig. 6b, c).
In addition to staining of lymphatic vessels, some Lyve-
1-positive single cells were seen in the tissue surrounding
both tongue and skin tumors. Lyve-1 is reported to be
expressed by tumor associated macrophages [29] and by
high-endothelial venules of lymph nodes [30]. There is also
evidence that lymphatic endothelial progenitor cells and
multi-potent mesenchymal stem cells can contribute to
formation of lymphatic vessels [31–34]. The Lyve-1-
positive single cells may represent one or several of these
cell types.
Increased expression of VEGF-C in tongue tumors
Three parallel tongue and skin tumors of each cell line were
stained with antibodies against VEGF-C and VEGF-D to
determine if different expression of these growth factors
could explain the observed distinction in lymphatic vessel
density between tongue and skin tumors from our xenograft
model. Three parallel tongue and skin tumors of each cell
line were stained with antibodies against VEGF-C and
VEGF-D. In all tumors, staining for both growth factors
was primarily seen in the cancer cells, but some stromal
cells were also positive (Fig. 7). The staining varied
between the parallels and no significant differences were
observed between tongue and skin tumors of the various
cell lines (data not shown).
To more precisely quantify the expression of VEGF-C
and VEGF-D, the mRNA level of both growth factors was
analyzed by RT-qPCR in five tongue tumors and four skin
tumors of the Ishikawa cell line. The expression of VEGF-
C mRNA was about twice as high in tongue tumors
compared with skin tumors (2.1±0.37 (mean±SEM)),
whereas no difference was found in the expression level
of VEGF-D (data not shown).
Table 5 Fraction of apoptotic cells
Cell line Mean±SEM P
Tongue Skin
SCC-25 23±84 24±9 0.957
HSC-4 63±24 90±66 0.679
UT-SCC-12A 20±6 30±10 0.456
UT-SCC-7 18±5 13±5 0.555
Ishikawa 43±13 55±27 0.708
Pooled 35±7 40±12 0.689
N=2 for SCC-25 skin, HSC-4 skin and UT-SCC-7 tongue, N=3 for
SCC-25 tongue, HSC-4 tongue, UT-SCC-12A tongue and skin, UT-
SCC-7 skin and Ishikawa tongue and skin. N=14 for pooled tongue
tumors and N=13 for pooled skin tumors
Table 4 Fraction of mitotic cells
Cell line Mean±SEM P
Tongue Skin
SCC-25 46±10 30±4 0.341
HSC-4 26±13 14±1 0.455
UT-SCC-12A 58±4 15±4 0.001
UT-SCC-7 100±53 47±5 0.422
Ishikawa 66±9 51±8 0.257
Pooled 61±12 31±5 0.038
N=3 for all cell lines, except SCC-25 skin where N=2. N=15 for
pooled tongue tumors and N=14 for pooled skin tumors
684 Virchows Arch (2010) 457:677–692Fig. 4 Blood vessel density. Pictures show representative immuno-
histochemical CD31 staining of a skin tumor and b tongue tumor of
the oral SCC cell line HSC-4. CD31 staining is shown in brown and
cell nuclei are stained blue. Tumor and stromal areas are indicated with
t and s, respectively. Original magnification, 100×. c CD31-positive
blood vessels within intratumoral stromal tissue of a tongue tumor of
the HSC-4 cell line. Original magnification, 400×. d CD31-negative
blood vessel within the same tumor as in c). Blood vessel without
CD31 staining is labeled with asterisk. Original magnification, 400×. e
Graph shows mean blood vessel density (MVD; ±SEM) of tongue
(black bars) and skin (grey bars) tumors of the different cell lines,
calculated by counting lumens containing red blood cells. N=5 for
SCC-25, UT-SCC-12A, UT-SCC-7 and Ishikawa tumors. N=3 for skin
tumors and N=5 for tongue tumors of the HSC-4 cell line. N=25 for
pooled tongue tumors, and N=23 for pooled skin tumors of all cell
lines. *P<0.05
Fig. 3 Lymphatic metastases. a Lymph node metastases from a
xenograft tongue tumor of the skin SCC cell line UT-SCC-12A
immunohistochemically stained with cytokeratin. Cytokeratin staining
is shown in brown and nuclei are stained blue. Original magnification,
100×. b Tongue lymphatic vessels immunohistochemically stained
with Lyve-1 containing UT-SCC-12A tumor cells (labeled t). Lyve-1
staining is shown in brown and cell nuclei are stained blue. Original
magnification, 400×
Virchows Arch (2010) 457:677–692 685Human tongue SCCs have higher lymphatic vessel density
than human skin SCCs
To investigate if the density of lymphatic vessels surrounding
skin and tongue SCCs in humans showed the same pattern as
in our mouse model, tumor tissue from patients with skin or
tongue SCCs were immunohistochemically stained with the
lymphatic endothelial cell marker podoplanin (D2–40)
(Fig. 8). This revealed that lymphatic vessel density was
significantly higher in tongue (17.9±1.8 (mean±SEM)) than
in skin (10.7±1.1) tumors (P=0.02).
Increased number of inflammatory cells in tongue tumors
compared with skin tumors in the xenograft model
It is well known that inflammatory mediators contribute
significantly to tumor progression [35, 36]. We therefore
studied the presence of different types of inflammatory cells
in the tongue and skin tumors in our xenograft model. For
all cell lines the inflammatory infiltrate was more pro-
nounced in tongue tumors compared with the
corresponding skin tumors. The number of neutrophils
was determined by morphological evaluation of H/E-
stained sections of skin and tongue tumors. The number
of neutrophils was two to three times higher in tongue
tumors compared with the corresponding skin tumors
(Fig. 9a). The number of tumor associated mast cells,
assessed by May–Grünwald–Giemsa staining, were also
higherintonguetumorscomparedwithskintumorsforallcell
lines, except the UT-SCC-7 cell line where the opposite was
seen(Table6). The number of macrophages, Langerhans and
dendritic cells, assessed by CD68-positive cells, was low in
both tongue and skin, and further quantification was
therefore not performed.
Fig. 5 Lymphatic vessel densi-
ty. Pictures show representative
immunohistochemical Lyve-1
staining of tumors of the HSC-4
cell line in a tongue and b skin.
Lyve-1 staining is shown in
brown and cell nuclei are
stained blue. Tumor and stromal
areas are indicated with t and
s, respectively. Original magni-
fication, 100×. c Graph
shows peritumoral mean
lymphatic vessel density
(±SEM) of tongue (black bars)
and skin (grey bars) tumors
of the various cell lines as
number of vessels per area. N=6
for SCC-25 and UT-SCC-12A
tumors, N=4 for UT-SCC-7
and Ishikawa tumors. N=6 for
HSC-4 tongue tumors, and N=3
for HSC-4 skin tumors. N=26
for pooled tongue tumors, and
N=24 for pooled skin tumors
of all cell lines. *P<0.05; **
P<0.005
686 Virchows Arch (2010) 457:677–692SAP is a major acute phase protein in mice. To
investigate if the intensity of the tumor associated inflam-
mation was reflected in the level of this protein, ELISAwas
used to quantify SAP in plasma from the tumor bearing
mice. This revealed that mice with tongue tumors of all cell
lines had a slight but consistently higher plasma level of
SAP than mice with corresponding skin tumors (Fig. 9b).
Discussion
Oral cancers mainly metastasize via lymphatic vessels to
regional lymph nodes, and there is a well-established
association between lymphatic vessel density, lymph node
metastases and overall prognosis for oral cancers [13, 37].
It is known that the tumor stroma has a profound impact on
Fig. 6 Lymphangiogenesis.
Pictures show representative
immunohistochemical Lyve-1
staining of tongue tumors of
the HSC-4 cell line after a
5d a y s ,b 10 days and c 15
days. Lyve-1 staining is shown
in brown and cell nuclei are
stained blue.T u m o ra n d
stromal areas are indicated with
t and s, respectively. Original
magnification, 100×
Fig. 7 Lymphatic endothelial
growth factors. Pictures show rep-
resentative immunohistohemical
staining with antibodies against
VEGF-C (a and b) and VEGF-D
(c and d)o ft u m o r so ft h eU T -
SCC-12A cell line in tongue (a
and c)a n ds k i n( b and d). VEGF-
C/-D staining is shown in brown
and cell nuclei are stained blue.
Tumor and stromal areas are indi-
cated with t and s, respectively.
Original magnification, 400×
Virchows Arch (2010) 457:677–692 687many aspects of cancer development and progression.
Lymphangiogenetic growth factors can be produced both
by tumor cells and stromal cells, although little is known
about the significance of tumor–stroma interactions for
lymphangiogenesis. Our xenograft model is well suited for
investigating stromal influence on this process. We found
that the lymphatic vessel density was much higher in
tongue tumors of all cell lines than in the corresponding
skin tumors. In the skin, there was a remarkable lack of
lymphatic vessels surrounding the majority of the tumors.
Those that were seen were mostly located in the sub-
epithelial connective tissue and probably represented pre-
existing vessels. In general, the tongue tumors were larger
than the skin tumors, and this could possibly contribute to
the stronger induction of lymphangiogenesis in tongue
tumors compared with skin tumors. However, the size
differences between tongue and skin tumors of the Ishikawa
and the UT-SCC-7 cell lines were rather small, but still the
tongue tumors induced much more lymphatic vessel
formation than the skin tumors. Therefore, it does not
appear to be any significant correlation between tumor size
and lymphangiogenesis in our model.
Many aspects of the molecular mechanisms of lymphan-
giogenesis are obscure. The best established inducers of
lymphangiogenesis are the growth factors VEGF-C and
VEGF-D, which can be produced by both tumor and
stromal cells. These growth factors mainly signal through
the VEGFR-3 receptor found on lymphatic endothelial cells
and induce proliferation and migration of these cells [17,
38, 39]. Blocking VEGFR-3 signaling has been shown in
many studies to inhibit lymphangiogenesis, indicating that
the VEGF-C/-D–VEGFR-3 signaling axis is essential for
formation of new lymphatic vessels [40, 41]. In the present
study, we found that the mRNA level of VEGF-C was
twice as high in tongue tumors compared with the
corresponding skin tumors. Immunohistochemical staining
for VEGF-C and VEGF-D showed no significant difference
in staining intensity between tongue and skin tumors. This
discrepancy in results at mRNA and protein level may be
due to the different sensitivities of the two methods.
VEGF-C and VEGF-D are secreted in an active form
that can bind VEGFR-3. However, they can be further
processed by proteases in the extracellular environment to a
mature form with higher affinity for VEGFR-3 [21, 42].
There was a more prominent inflammatory reaction
surrounding the tongue tumors compared with the skin
tumors, where neutrophils and mast cells comprised a high
proportion of the inflammatory cells. These cell types are
known to produce a number of proteolytic enzymes,
including MMP-2, MMP-9, MMP-25, tryptases and
chymases [43–45]. Higher levels of such proteases in
tongue tumors than in skin tumors may result in an
increased proteolytic processing of VEGF-C and VEGF-D
to the more active forms, and subsequent enhanced
lymphangiogenetic signaling in the tongue. In a separate
study using the same xenograft model, we have actually
shown a significantly increased proteolytic activity in
tongue tumors compared with skin tumors [46]. Proteolytic
activity is also fundamental for cell migration and for the
tissue remodeling required for formation of new vessels
[47].
Our analysis of tumors from patients with oral and skin
SCCs showed that lymphatic vessel density was signifi-
cantly higher in tongue compared with skin SCCs (Fig. 8),
Fig. 8 Lymphatic vessels in
human SCCs. Pictures show
representative immunohisto-
chemical staining with antibody
against podoplanin (D2-40) of
tumor tissue from patients with
tongue SCC (a) and skin SCC
(b). Podoplanin staining is
shown in brown and cell nuclei
are stained blue. Tumor and
stromal areas are indicated with
t and s, respectively, asterisks
indicate area with prominent
inflammatory infiltrate. Original
magnification, 100×
688 Virchows Arch (2010) 457:677–692suggesting that our xenograft model reflects clinically
relevant aspects of lymphangiogenesis in oral and
cutaneous SCCs. The increased lymphangiogenesis in
tongue tumors may contribute to the different metastatic
potential of tongue and skin SCCs. Patients with oral
SCCs may therefore benefit from treatment targeting
lymphangiogenesis.
There are many studies highlighting the importance of
angiogenesis in cancer growth and progression [7]. The
transition from small dormant tumors to actively growing,
invasive and metastatic tumors is shown to be associated
with the so-called angiogenic switch, which implies that
cancer cells gain the ability to induce formation of new
blood vessels [7, 48]. Blood vessel density is further found
to correlate with invasiveness and metastasis of many
cancers [49–52]. We therefore hypothesized that the differ-
ences in growth rate and invasiveness between the tongue
and skin tumors in our experiments could be explained by a
difference in vascularisation of the tumors in the two
organs. To our surprise, we found that the skin tumors were
more vascularised than the tongue tumors. Even the
smallest and most encapsulated skin tumors had numerous
Table 6 Mast cell number
Cell line Mean±SEM P
Tongue Skin
SCC-25 6±1 3±0.5 0.140
HSC-4 13±2 4±1 0.014
UT-SCC-12A 3±1 2±1 0.711
UT-SCC-7 5±1 7±2 0.545
Ishikawa 5±2 3±1 0.489
Pooled 6±1 4±1 0.058
N=3 for all cell lines. N=15 for pooled tongue and skin tumors
Fig. 9 Assessment of inflam-
mation. a Graph shows mean
neutrophil numbers (±SEM) of
tongue (black bars) and skin
(grey bars) tumors of the
various cell lines. N=3 for all
cell lines, and N=15 for pooled
tongue and skin tumors. *P<
0.05. b The graph shows mean
plasma level of SAP in ng/ml×
10
4 (±SEM) in mice with tongue
(black bars) and skin (grey bars)
tumors of the various cell lines.
N=3 for all cell lines, except
UT-SCC-7 where N=2, and
N=14 for pooled tongue and
skin tumors
Virchows Arch (2010) 457:677–692 689blood vessels surrounding them. A clear relationship
between mean vessel density and prognosis for patients
with oral SCCs is not established, as different studies report
conflicting results [53–55]. Sparse vascularisation or rapidly
growing tumors can result in areas with hypoxic conditions
[56]. Hypoxia provokes adaptive systems in the cancer cells
and induces production of substances that regulate metabo-
lism, angiogenesis, pH, cell migration and cell survival [56].
Hypoxia is therefore generally accepted as a promoter of
tumor growth, though it can also induce apoptosis [57]. The
lower vessel density in the tongue tumors may induce
hypoxia which further stimulates a more aggressive progres-
sion of the tongue cancers compared with the skin cancers.
In accordance with this hypothesis, two recent studies
showed that the use of antiangiogenic therapy resulted in
increased local invasion and distant metastases in experi-
mental mouse models [58, 59].
We found that tumors grew faster in the tongue than in the
skin irrespective of the tumor cells’ origin. Our results
therefore challenge the established belief that cancer cells
grow better in ortotopic than in heterotopic environments. To
our knowledge there are few studies addressing heterotopic
growth of cancer cells in organs associated with aggressive
cancers. Our results indicate that the tongue offers a more
favorable microenvironment for tumor growth than the skin,
which is reflected in the clinical behavior of tongue and skin
SCCs in humans. This may partly be related to different
structural factors such as different composition of the ECM,
resident immunity, temperature and exposure to light or
trauma. This further highlights the important role of the
stroma in directing growth and progression of cancers.
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